News |

Jodi Westfall, NP, explains how she improves common skin conditions traditionally and from a metabolic perspective.

Three major NDAs and sBLAs were accepted by the FDA in Q1 of 2023, with PDUFA dates set in 2023 and 2024.

Learn more about the in-depth topics covered in the March 2023 issue of Dermatology Times®.

In the final part of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

The device, produced by Sensus Healthcare, is cloud-based and utilizes OpenAI technology.

In a clinical study conducted in Japan, researchers found the treatment well-tolerated and efficacious in moderate-to-severe cases.

Researchers say adolescents and young adults using the dermocosmetic product experienced improvements in their acne and quality of life.

In this week’s Pointers with Dr Portela, the 208SkinDoc picks his top products for repairing sun-damaged skin.

The robotic device was previously cleared to treat patients' full abdomen and flanks.

Researchers investigated the injection’s impact on the upper face.

There are currently no FDA approved therapies in this treatment setting.

When a patient complains of breast pain, there are several special considerations for diagnosis and treatment.

Check out new, trending, and up-and-coming perspectives on the use of laser therapies in several dermatologic conditions.

Medical practices can choose from a wide array of tools to enable communication with patients from diverse backgrounds.

Learning how to prescribe biologics, talking to mentors, reviewing journals, and getting involved in clinical trials are all ways to boost your expertise.

Silverberg discusses how certain irritants and living situations may cause flares in patients with atopic dermatitis.

The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.

Researchers determined a statistically significant improvement to patient quality of life post-transplant.

Late-breaking positive phase 2a results were presented at AAD 2023.

AbbVie announced study results demonstrating efficacy in patients with a history of previous interleukin-17 inhibitor therapy.

Click here to answer this week's poll.

Although the ingredient is widely used in skincare, the American Contact Dermatitis Society (ACDS) wants clinicians to take special considerations when patch testing for lanolin contact allergy.

Researchers say women who experience hair loss may experience conditions like acne, breast cancer, and diabetes.

Research suggests that as metal allergies and implants grow in frequency, some patients may need to consult a dermatologist for treatment.

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

The study also found lasting benefits of the supplement for bone density up to age 4.